Search Results

Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”), announced today it has entered into a research collaboration agreement with Manhattan BioSolutions, Inc. (Manhattan Bio), an emerging biotech company focused on precision biologics, to explore antibody-drug conjugates (ADCs) using Nascent’s lead clinical candidate pritumumab (PTB) as the tumor-targeting antibody element.

As the Trump administration—including HHS Secretary Robert F. Kennedy Jr.—plays fast and loose with scientific studies and facts, there may be a more sinister force at play: censorship.

The FDA approved the use of Opdivo with Yervoy in front-line colorectal cancer, while a Manhattan court junked a class action complaint over the blood cancer drug Pomalyst.

Manhattan Scientifics Inc. (OTCQB: MHTX), which provided the initial funding &, currently owns more than 50 million shares of Imagion Biosystems Ltd. celebrates Imagion’s remarkable progress in early cancer detection technology.